Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
Department of Biomedicine, University of Bergen, Jonas Lies Vei 91, 5009 Bergen, Norway
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(19), 4986; https://doi.org/10.3390/cancers13194986
Submission received: 17 August 2021
/
Revised: 29 September 2021
/
Accepted: 1 October 2021
/
Published: 5 October 2021
(This article belongs to the Special Issue Immunological, Molecular and Imaging Biomarkers of Malignant Progression in Brain Cancer: Improving Precision Neuro-Oncology)
Simple Summary
Designer T and NK cells are a modality within immunotherapy that manipulates receptor-ligand interactions to enhance cells of the immune system to destroy cancer more effectively. Patient’s own immune cells are isolated, genetically modified to improve responses against cancers cells, expanded, and subsequently reintroduced into the individual. Several clinical trials to investigate immunotherapy strategies that may garner lasting benefit even for cancer patients with glioblastoma (GBM), a deadly brain cancer with limited treatment options, are underway. Therapeutic potential for gene editing technologies in limiting rejection and adverse reactions to improve treatment responses in preclinical models is now translating into enduring efficacy in GBM patients.
Abstract
Glioblastoma (GBM) is the most prevalent, aggressive primary brain tumour with a dismal prognosis. Treatment at diagnosis has limited efficacy and there is no standardised treatment at recurrence. New, personalised treatment options are under investigation, although challenges persist for heterogenous tumours such as GBM. Gene editing technologies are a game changer, enabling design of novel molecular-immunological treatments to be used in combination with chemoradiation, to achieve long lasting survival benefits for patients. Here, we review the literature on how cutting-edge molecular gene editing technologies can be applied to known and emerging tumour-associated antigens to enhance chimeric antigen receptor T and NK cell therapies for GBM. A tight balance of limiting neurotoxicity, avoiding tumour antigen loss and therapy resistance, while simultaneously promoting long-term persistence of the adoptively transferred cells must be maintained to significantly improve patient survival. We discuss the opportunities and challenges posed by the brain contexture to the administration of the treatments and achieving sustained clinical responses.
